Viktor Golmakher

Title: Viktor Golmakher: Innovator in Cancer Treatment

Introduction

Viktor Golmakher is a notable inventor based in Newton, MA, who has made significant contributions to the field of cancer treatment. His innovative work focuses on the development of anti-CD38 antibodies, which have the potential to revolutionize therapies for various cancers and autoimmune diseases.

Latest Patents

Golmakher holds a patent for "Anti-CD38 antibodies for the treatment of cancer." This patent encompasses humanized antibodies, resurfaced antibodies, antibody fragments, and derivatized antibodies that specifically bind to CD38. These antibodies are capable of inducing apoptosis and mediating cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The applications of these antibodies extend to treating tumors expressing CD38 protein, including multiple myeloma and various forms of leukemia, as well as autoimmune and inflammatory diseases such as systemic lupus and rheumatoid arthritis.

Career Highlights

Viktor Golmakher is currently associated with Sanofi Aventis, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on cancer therapies, particularly in targeting CD38-expressing cells.

Collaborations

Golmakher has collaborated with esteemed colleagues, including Peter U Park and Laura M Bartle, to further enhance the research and development of his innovative treatments.

Conclusion

Viktor Golmakher's contributions to the field of cancer treatment through his patented anti-CD38 antibodies highlight his role as a leading inventor in medical innovation. His work promises to improve therapeutic options for patients suffering from various cancers and autoimmune diseases.